COMPANY STATEMENT

August 8, 2023

Statement on Transfer of Bard PowerPort™ Implantable Port Cases to Multi-District Litigation

Our portfolio of Bard PowerPort™ devices have a long and successful history of enabling the treatment of critically ill patients, particularly those with cancer. These devices are cleared for use by the U.S. Food and Drug Administration (FDA), and we are confident in both their design and the appropriateness of our communication of their risks and benefits.

Importantly, there has been no recall of any Bard PowerPort™ device due to catheter fracture. We actively monitor and investigate all reported complaints regarding our Bard PowerPort™ devices and continue to report adverse events as required by the FDA. We have identified no new safety risks related to our Bard PowerPort™ devices that are not already identified and communicated in each device's instructions for use (IFU). All implantable medical devices — including vascular access port devices — carry inherent risks but also offer important clinical benefits that can outweigh those risks. The complications alleged in recent legal filings are known risks that are communicated to health care practitioners in the IFUs of our Bard PowerPort™ devices. We clearly communicate the risks and benefits of our Bard PowerPort™ devices so physicians, in consultation with their patients, can determine whether those benefits outweigh the potential risks in a particular instance.

We respectfully disagree with the court's decision to transfer these cases into a multi-district litigation, and we will continue to vigorously defend these cases. Bard PowerPort™ devices have benefited countless patients, and while we are empathetic to any patient who experiences a medical complication following the use of one of our devices, we stand behind the safety and efficacy of these products.

# # #